连续流左心室辅助装置18个月临床结局比较
该回顾性研究比较了105例植入连续流左心室辅助装置(LVAD)患者18个月结局,其中HM2占51%、HW占24%、HM3占25%。HM3组卒中与血栓风险显著低于HM2和HW组,且无卒中或装置交换生存率更高。
要点
- HM3组卒中风险0%,显著低于HM2的26%和HW的40%。
- HM3组血栓风险0%,显著低于HM2的31%和HW的12%。
- HM3组无卒中或装置交换生存率优于HM2和HW。
核心结论
- HM3装置相比HM2或HW LVAD呈现更好的预后和不良事件特征。
研究设计与样本
- 研究者发起的单中心回顾性比较分析,纳入2008至2017年植入连续流LVAD的患者105例,随访18个月。
主要发现
- HM3组卒中风险0%,低于HM2组的26%(P<0.001)和HW组的40%(P<0.001)。
- HM3组血栓风险0%,低于HM2组的31%(P<0.001)和HW组的12%(P<0.001)。
- 血液相容性累积评分HM3为5、HM2为89、HW为56(P<0.001)。
- HM3组相比HW组非计划住院次数更少,中位数1次(IQR 0-2)对3次(IQR 2-4),P=0.012。
临床怎么用
- 在真实世界中选择连续流LVAD时,HM3可能提供更优的卒中与血栓预防及生存结局。
局限性
- 结论需更大规模头对头比较研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In this study, we aimed to determine the comparative outcomes of patients supported with continuous-flow left ventricular assist devices (LVADs): HeartMate 2 (HM2), HeartWare (HW) and HeartMate 3 (HM3) in a real-world setting. METHODS: The study was an investigator-initiated comparative retrospective analysis of patients who underwent continuous-flow LVAD implantation at our institution between 2008 and 2017. The follow-up duration was 18 months after implantation. RESULTS: The study included 105 continuous-flow LVAD-supported patients of whom 51% (n = 54), 24% (25) and 25% (26) underwent implantation of HM2, HW and HM3, respectively. During follow-up, patients who were supported with HM3 versus either HM2 or HW LVADs demonstrated a lower risk of stroke (0% vs 26%, P < 0.001 and 0% vs 40%, P < 0.001, respectively) and lower rates of thrombosis (0% vs 31%, P < 0.001 and 0% vs 12%, P < 0.001, respectively), findings that were consistent with their calculated haemocompatibility scores (cumulative score 5, 89 and 56 for HM3, HM2 and HW, respectively, P < 0.001). Moreover, patients supported with HM3 versus HW had fewer unplanned hospitalizations [median 1 (25th-75th interquartile range 0-2) vs 3 (interquartile range 2-4), P = 0.012]. Importantly, survival free from stroke or device exchange was higher in patients supported with HM3 compared with either the HM2 or the HW LVADs [hazard ratio (HR) 2.77, confidence interval (CI) 1.13-6.78; P = 0.026 and HR 2.70, CI 1.01-7.20; P = 0.047, respectively]. CONCLUSIONS: HM3 device currently presents better prognostic and adverse events profiles when compared with the HM2 or the HW LVADs. A larger-scale head-to-head comparison between the devices is warranted in order to confirm our findings.
引用
- Itzhaki Ben Zadok O, Ben-Avraham B, Shaul A, et al. An 18-month comparison of clinical outcomes between continuous-flow left ventricular assist devices. Eur J Cardiothorac Surg. 2019. PMID: 31566245. doi:10.1093/ejcts/ezz268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。